🔗 Permalink

Inventor profile of:

Steven A. Rosenberg

City:

Potomac, Maryland

Country:

United States

Published Applications:

164

Last publication date:

2026-05-28

Top Assignees for applications by Steven A. Rosenberg

The entities that hold a legal rights for patent applications filed by inventor Rosenberg Steven A.:

The United States of America,as represented by the Secretary,Department of Health and Human Services 51 Bethesda, MD United States
The United States of America, as represented by the Secretary, Department of Health and Human Services 49 Bethesda, MD United States
The United States of America, as represented by the Secretary, Department of Health and Human Services 33 Washington, DC United States
The United States of America as Represented by the Department of Health and Human Services 15 Washington, DC United States
The United States of America, as represented by the Secretary, Department of Health and Human Serv 12 Bethesda, MD United States
Regents of the University of Minnesota 11 Minneapolis, MN United States
Intima Bioscience, Inc. 11 New York, NY United States
The United States of America, as represented by the Secretary, Dept. of Health and Human Services 7 Bethesda, MD United States
The United States of America, as represented by the Secretary, Department of Health and Human Servic 7 Bethesda, MD United States
GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. 6 Rockville, MD United States
The United States of America, as represented by the Secretary, Department of Health and Human 4 Bethesda, MD United States
The United States of America,as represented by the Secretary,Department of Health and Human Service 4 Bethesda, MD United States
The United States of Americans represented by the Secretary, Department of Health and Human Services 4 Bethesda, MD United States
Wilson Wolf Manufacturing Corporation 3 New Brighton, MN United States
Human Services 2 Bethesda, MD United States
YEDA RESEARCH AND DEVELOPMENT CO. LTD. 2 Rehovot, Israel
Immunocore Limited 2 Oxfordshire, United Kingdom
The USA, as represented by the Secretary, Dept. of Health and Human Services 2 Bethesda, MD United States
The USA, as represented by the Secretary, Department of Health and Human Services 2 Bethesda, MD United States
The United States of America, as represented by the Secretary, Dept. of Health & Human Services 2 Bethesda, MD United States
The United States of America as represented by the Secretary of the Department of Health and Human Services 2 Washington, DC United States
The United States of America, as Represented by the Secretary, Department of Health & Human Services 2 Bethesda, MD United States
Human Service 1 Bethesda, MD United States
The United States of America, as rep., by the Secretary, Dept., of Health and Human Services. 1 Bethesda, MD United States
The United States of America, as represented by the Secretary, Department of Health & Human Servic 1 Bethesda, MD United States
The United State of America, as represented by The Secretary, Department of Health and Human Service 1 Bethesda, MD United States
United States of America, Represented by the Secretary, Department of Health and Human Services 1 Washington, DC United States
The U.S.A., as represented by the Secretary, Department f Health and Human Services 1 Bethesda, MD United States
The U.S.A., as represented by the Secretary, Department of Health and Human Service 1 Bethesda, MD United States
The U.S.A., as represented by the Secretary, Depart. of Health and Human Service 1 Bethesda, MD United States
The United States of America,as represented by the the Secretary, Department of Health and Human Ser 1 Bethesda, MD United States
The United States of America as represented by the Secretary, Department of Health and Human Service 1 Bethesda, MD United States
The United States of America, as represented by the Secretary, Deparment of Health and Human Services 1 Washington, DC United States
The Government of the United States of America, as represented by the Secretary, Department of Healt 1 Rockville, MD United States
The United States of America, as represented by the Secretary, Dept. of Health and Human Services 1 Rockville, MD United States
The United States of America as represented by the Secretary, Department of Health & Human Services 1 Washington, DC United States
Government of the United States of America, represented by the Secretary, Department of Health 1 Rockville, MD United States
The United States of America, a represented by the Secretary, Department of Health and Human Servi 1 Bethesda, MD United States
Government of the United States of America, Repres ented by The Secretary, Department of Health 1 Rockville, MD United States
of Health and Human Services Office of Technology Transfer 1 Rockville, MD United States
THE US OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES 1 Bethesda, MD United States
Health and Human Services 1 Bethesda, MD United States
GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SEC. DEPT. OF HEALTH AND HUMANS 1 ROCKVILLE, MD United States
GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRE- SENTED BY THE SECRETARY DHHS 1 ROCKVILLE, MD United States
The United States of America,as Represented by the Secretary, Department of Health and Human Servic 1 Bethesda, MD United States
GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPA 1 Rockville, MD United States
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH 1 Bethesda, MD United States
The United States of America, as represented by the Secretary, Department of Health and Human Servces 1 Bethesda, MD United States
The United States of America as represented by the Secretary of Health and Human Services 1 Washington, DC United States
The United State of America, as represented by the Secretary, Department of Health and Human Services 1 Washington, DC United States
The United States of America, as represented by the Secretary, Department of Health and Human Serice 1 Bethesda, MD United States
The United States of America, as Represented by the Secretary, Dept. of Health & Human Service 1 Bethesda, MD United States
Government of the U.S.A, represented by the Secretary, Dept. of Health & Human Services 1 Rockville, MD United States
The United States of America, as represent by the Secretary, Department of Health and Human servic 1 , -

Recent patent applications by Rosenberg Steven A.

Steven A. Rosenberg from Potomac, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-05-28

US20260146073A1

Chemistry; metallurgy

T CELL RECEPTORS TARGETING MUTATED CDKN2A

#2 | 2026-01-08

US20260008832A1

Chemistry; metallurgy

HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION

#3 | 2026-01-01

US20260001930A1

Chemistry; metallurgy

T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3

#4 | 2025-11-06

US20250340611A1

Chemistry; metallurgy

ANTI-KRAS-G12D T CELL RECEPTORS

#5 | 2025-08-07

US20250250318A1

Chemistry; metallurgy

HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS

#6 | 2025-05-01

US20250136938A1

Chemistry; metallurgy

METHODS OF ENRICHING CELL POPULATIONS FOR CANCER-SPECIFIC T CELLS USING IN VITRO STIMULATION OF MEMORY T CELLS

#7 | 2025-02-20

US20250059508A1

Chemistry; metallurgy

METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION

#8 | 2025-02-20

US20250057949A1

Human necessities

T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY AGAINST CANCER

#9 | 2024-11-21

US20240382577A1

Human necessities

METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS

#10 | 2024-08-15

US20240270814A1

Chemistry; metallurgy

T CELL RECEPTORS RECOGNIZING MUTATED P53

#11 | 2024-08-08

US20240263136A1

Chemistry; metallurgy

METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME

#12 | 2024-08-01

US20240254190A1

Chemistry; metallurgy

T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53

#13 | 2024-06-27

US20240209059A1

Chemistry; metallurgy

ANTI-KRAS-G12D T CELL RECEPTORS

#14 | 2024-06-13

US20240190940A1

Chemistry; metallurgy

HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION

#15 | 2024-04-18

US20240124935A1

Chemistry; metallurgy

METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES

#16 | 2023-12-21

US20230406904A1

Chemistry; metallurgy

T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS

#17 | 2023-11-16

US20230365649A1

Chemistry; metallurgy

HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION

#18 | 2023-10-26

US20230340066A1

Chemistry; metallurgy

Anti-human papillomavirus 16 E6 T cell receptors

#19 | 2023-10-12

US20230321240A1

Human necessities

T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53

#20 | 2023-09-28

US20230303976A1

Chemistry; metallurgy

METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD

#21 | 2023-08-31

US20230272038A1

Chemistry; metallurgy

HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION

#22 | 2023-08-24

US20230265387A1

Chemistry; metallurgy

METHODS OF PRODUCING ENRICHED POPULATIONS OF TUMOR-REACTIVE T CELLS FROM TUMOR

#23 | 2023-08-17

US20230258635A1

Physics

T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY

#24 | 2023-08-17

US20230257440A1

Chemistry; metallurgy

HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION

#25 | 2023-06-29

US20230203124A1

Chemistry; metallurgy

METHODS OF ISOLATING T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION

#26 | 2023-06-15

US20230183802A1

Chemistry; metallurgy

METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY

#27 | 2023-05-25

US20230159614A1

Chemistry; metallurgy

HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION

#28 | 2023-05-04

US20230139588A1

Human necessities

Methods of preparing anti-human papillomavirus antigen T cells

#29 | 2023-05-04

US20230138309A1

Chemistry; metallurgy

METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY

#30 | 2023-03-16

US20230082787A1

Chemistry; metallurgy

HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION

#31 | 2023-03-16

US20230080742A1

Chemistry; metallurgy

HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION

#32 | 2023-01-26

US20230026180A1

Chemistry; metallurgy

HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS

#33 | 2022-11-24

US20220372103A1

Chemistry; metallurgy

ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS

#34 | 2022-11-17

US20220362297A1

Human necessities

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY

#35 | 2022-10-20

US20220332785A1

Chemistry; metallurgy

T CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN P53

#36 | 2022-09-08

US20220282208A1

Chemistry; metallurgy

METHODS OF ISOLATING T CELL POPULATIONS

#37 | 2022-06-30

US20220204584A1

Chemistry; metallurgy

HLA class II-restricted t cell receptors against mutated RAS

#38 | 2022-06-23

US20220195008A1

Chemistry; metallurgy

T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3

#39 | 2022-04-28

US20220125843A1

Human necessities

MODIFIED CELLS AND METHODS OF THERAPY

#40 | 2022-04-07

US20220105133A1

Human necessities

TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY

#41 | 2022-03-24

US20220089677A1

Chemistry; metallurgy

Anti-KRAS-G12D T cell receptors

#42 | 2022-03-24

US20220089673A1

Chemistry; metallurgy

HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION

#43 | 2021-12-16

US20210388113A1

Chemistry; metallurgy

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

#44 | 2021-11-04

US20210338797A1

Human necessities

Methods of preparing anti-human papillomavirus antigen T cells

#45 | 2021-11-04

US20210338796A1

Human necessities

Methods of preparing anti-human papillomavirus antigen T cells

#46 | 2021-11-04

US20210338795A1

Human necessities

Methods of preparing anti-human papillomavirus antigen t cells

#47 | 2021-09-30

US20210300988A1

Chemistry; metallurgy

Anti-KRAS-G12D T cell receptors

#48 | 2021-08-26

US20210260117A1

Human necessities

Modified cells and methods of therapy

#49 | 2021-07-22

US20210220457A1

Human necessities

Methods of isolating T cells having antigenic specificity for a cancer-specific mutation

#50 | 2021-05-06

US20210130433A1

Chemistry; metallurgy

Anti-human papillomavirus 16 E6 T cell receptors

#51 | 2021-05-06

US20210130432A1

Chemistry; metallurgy

Anti-human papillomavirus 16 E7 T cell receptors

#52 | 2021-04-29

US20210121559A1

Human necessities

Methods of preparing anti-human papillomavirus antigen T cells

#53 | 2021-03-18

US20210079058A1

Chemistry; metallurgy

HLA class I-restricted t cell receptors against mutated RAS

#54 | 2021-02-25

US20210052642A1

Human necessities

Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells

#55 | 2020-11-12

US20200353001A1

Human necessities

Intracellular genomic transplant and methods of therapy

#56 | 2020-10-22

US20200330517A1

Human necessities

TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY

#57 | 2020-10-15

US20200323908A1

Human necessities

Methods of producing enriched populations of tumor reactive T cells from peripheral blood

#58 | 2020-10-08

US20200316121A1

Human necessities

METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION

#59 | 2020-10-01

US20200306310A1

Human necessities

Intracellular genomic transplant and methods of therapy

#60 | 2020-10-01

US20200306309A1

Human necessities

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY

#61 | 2020-09-17

US20200289571A1

Human necessities

TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY

#62 | 2020-09-17

US20200289570A1

Human necessities

Tumor infiltrating lymphocytes and methods of therapy

#63 | 2020-09-03

US20200277352A1

Chemistry; metallurgy

T cell receptors recognizing mutated P53

#64 | 2020-08-27

US20200270329A1

Chemistry; metallurgy

T CELL RECEPTORS RECOGNIZING MHC CLASS II-RESTRICTED MAGE-A3

#65 | 2020-08-13

US20200254018A1

Human necessities

Methods for selectively expanding cells expressing a TCR with a murine constant region

#66 | 2020-08-06

US20200247869A1

Chemistry; metallurgy

Anti-KRAS-T cell receptors

#67 | 2020-05-21

US20200157241A1

Chemistry; metallurgy

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

#68 | 2020-05-14

US20200148739A1

Chemistry; metallurgy

T cell receptors recognizing HLA-CW8 restricted mutated KRAS

#69 | 2020-03-26

US20200095548A1

Chemistry; metallurgy

Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood

#70 | 2020-02-20

US20200056237A1

Chemistry; metallurgy

Methods of isolating neoantigen-specific T cell receptor sequences

#71 | 2020-01-16

US20200017831A1

Chemistry; metallurgy

Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same

#72 | 2019-12-12

US20190374576A1

Human necessities

VIRAL METHODS OF T CELL THERAPY

#73 | 2019-11-14

US20190345444A1

Chemistry; metallurgy

Methods of growing tumor infiltrating lymphocytes in gas-permeable containers

#74 | 2019-10-10

US20190309043A1

Chemistry; metallurgy

Anti-human papillomavirus 16 E6 T cell receptors

#75 | 2019-06-13

US20190177395A1

Chemistry; metallurgy

Anti-KRAS-G12D T cell receptors

#76 | 2019-04-25

US20190117761A1

Human necessities

METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS

#77 | 2019-03-21

US20190085047A1

Chemistry; metallurgy

Anti-human papillomavirus 16 E7 T cell receptors

#78 | 2019-03-21

US20190085046A1

Chemistry; metallurgy

HLA class II-restricted T cell receptors against mutated RAS

#79 | 2019-02-28

US20190060364A1

Human necessities

Intracellular genomic transplant and methods of therapy

#80 | 2019-02-28

US20190060363A1

Human necessities

Intracellular genomic transplant and methods of therapy

#81 | 2019-02-21

US20190054143A1

Human necessities

Anti-SSX-2 T cell receptors and related materials and methods of use

#82 | 2019-02-21

US20190054122A1

Human necessities

Intracellular genomic transplant and methods of therapy

#83 | 2019-02-07

US20190040111A1

Chemistry; metallurgy

T cell receptors recognizing HLA-Cw8 restricted mutated KRAS

#84 | 2019-01-17

US20190016777A1

Chemistry; metallurgy

T cell receptors recognizing HLA-A1- or HLA-CW7-restricted mage

#85 | 2019-01-10

US20190008899A1

Human necessities

Tumor infiltrating lymphocytes and methods of therapy

#86 | 2018-12-27

US20180371050A1

Chemistry; metallurgy

Murine anti-NY-ESO-1 T cell receptors

#87 | 2018-05-31

US20180148690A1

Chemistry; metallurgy

Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood

#88 | 2018-05-17

US20180133253A1

Human necessities

Methods of producing enriched populations of tumor reactive T cells from peripheral blood

#89 | 2018-05-10

US20180127479A1

Chemistry; metallurgy

T cell receptors recognizing MHC class II-restricted MAGE-A3

#90 | 2018-04-05

US20180094041A1

Chemistry; metallurgy

Anti-human papillomavirus 16 E6 T cell receptors

#91 | 2017-09-21

US20170267739A1

Chemistry; metallurgy

Chimeric antigen receptors to control HIV infection

#92 | 2017-08-10

US20170224800A1

Human necessities

Methods of isolating T cells having antigenic specificity for a cancer-specific mutation

#93 | 2017-08-03

US20170218042A1

Chemistry; metallurgy

METHODS OF ISOLATING T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION

#94 | 2017-06-22

US20170174771A1

Chemistry; metallurgy

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

#95 | 2017-06-01

US20170152478A1

Chemistry; metallurgy

METHODS OF GROWING TUMOR INFILTRATING LYMPHOCYTES IN GAS-PERMEABLE CONTAINERS

#96 | 2017-05-25

US20170145070A1

Chemistry; metallurgy

Anti-human papillomavirus 16 E7 T cell receptors

#97 | 2017-05-11

US20170130200A1

Chemistry; metallurgy

Intracellular genomic transplant and methods of therapy

#98 | 2017-03-09

US20170067021A1

Chemistry; metallurgy

Modified cells and methods of therapy

#99 | 2017-03-09

US20170065636A1

Human necessities

Modified cells and methods of therapy

#100 | 2017-02-02

US20170029483A1

Chemistry; metallurgy

Murine anti-NY-ESO-1 T cell receptors

InventorID:

236044 ⎘